-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 9th, Winbond Health announced that Winbond Pharmaceuticals, a wholly-owned subsidiary, has recently received the "Notice of Supplementary Application Approval" for methylprednisolone sodium succinate for chemical injections approved and issued by the National Medical Products Administration.
The drug passed the consistency evaluation of generic drugs
.
Methylprednisolone sodium succinate for injection is a kind of freeze-dried powder of glucocorticoid drugs.
It has strong anti-inflammatory, anti-allergic, anti-shock, and immunosuppressive effects.
It is clinically used in acute and critically ill patients.
Period, and maintenance treatment after first aid
.
Mainly used for anti-inflammatory therapy, immunosuppressive therapy, blood disease, tumor, shock therapy, endocrine disorders
The original manufacturer of methylprednisolone sodium succinate for injection was Pfizer, USA.
It was first listed in the US in 1959 and was approved for import in China in 1999
.
According to the enlarged version of the hospital data (including urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers) on Minai.